Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-Escalation Study of AQ4N Administered Intravenously in Patients With Advanced Malignancies

NCT00090727 is registered in ClinicalTrials.gov with Novacea as lead sponsor.

NCT NCT00090727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00090727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-Escalation Study of AQ4N Administered Intravenously in Patients With Advanced Malignancies
Lead sponsor
Novacea
Phase
Phase 1
Overall status
Unknown status
Start date
August 31, 2004
Completion date
Not reported
Enrollment
45
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma, solid malignancies